PATENT CLAIM ANALYSIS

Application Number: 15874299
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "264100"]

Abstract:
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.

Claim (Index 25):
The compound of  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1  and R 4  are each C 1-3  alkyl.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 86.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15047892', '15047903', '15408001', '14132653', '15712290']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7890551630390759
- 35 USC 102 Novelty (BERT): 0.5870551429674825
- Combined Prediction Score: 0.7688551610319165
- Mean Citation Score: 439.730804
- Max Citation Score: 488.92752
- Similarity Product: 425.5048754793835

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test